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Tocotrienol-rich fraction (TRF) has demonstrated antiproliferative effect on prostate cancer (PCa) cells. To elucidate this anticancer
property in PCa cells, this study aimed, first, to identify the most potent isomer for eliminating PCa cells; and second, to decipher the
molecular pathway responsible for its activity. Results showed that the inhibitory effect of g-tocotrienol was most potent, which
resulted in induction of apoptosis as evidenced by activation of pro-caspases and the presence of sub-G1 cell population. Examination
of the pro-survival genes revealed that the g-tocotrienol-induced cell death was associated with suppression of NF-kB, EGF-R and Id
family proteins (Id1 and Id3). Meanwhile, g-tocotrienol treatment also resulted in the induction of JNK-signalling pathway and
inhibition of JNK activity by a specific inhibitor (SP600125) was able to partially block the effect of g-tocotrienol. Interestingly,
g-tocotrienol treatment led to suppression of mesenchymal markers and the restoration of E-cadherin and g-catenin expression,
which was associated with suppression of cell invasion capability. Furthermore, a synergistic effect was observed when cells were co-
treated with g-tocotrienol and Docetaxel. Our results suggested that the antiproliferative effect of g-tocotrienol act through multiple-
signalling pathways, and demonstrated for the first time the anti-invasion and chemosensitisation effect of g-tocotrienol against PCa
cells.
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Prostate cancer (PCa) is the most common type of cancer in
developed countries. It is responsible for more male deaths than
any other cancers, except for lung and bronchial cancer (Ries et al,
2006). Most PCas present themselves as mixtures of androgen-
dependent and androgen-independent cells during clinical diag-
nosis. They initially respond to androgen ablation therapy by
undergoing programmed cell death (apoptosis) (Craft et al, 1999).
However, patients with advanced PCa develop hormonal refractory
disease that results in a fatal effect because of the growth of
androgen-independent PCa cells (Feldman and Feldman, 2001).
Until recently, the only chemotherapeutic drug that shows
improvement in survival of patients, Docetaxel, can only extend
the overall survival by 2 1/2 months (Chowdhury et al, 2007).
Furthermore, the treatment is associated with significant side
effects. Therefore, an alternative methodology to enhance the
apoptotic response is necessary to develop new therapeutic drugs
for the treatment of PCa.
Natural products have historically been a rich source of
biologically active compounds for drug discovery (Schiff et al,
1979). Tocotrienols (T3) are important plant vitamin-E constitu-
ents found in palm oil. Together with tocopherols (T), they provide
a significant source of antioxidant activity to all living cells
(Ahmad et al, 2005; Mazlan et al, 2006). This common antioxidant
attribute reflects the similarity in chemical structures of the
tocotrienols and the tocopherols, which differ only in their
structural side chain (contains farnesyl for tocotrienol or saturated
phytyl side chain for tocopherol). The common hydrogen atom
from the hydroxyl group on the chromanol ring acts to scavenge
the chain-propagating peroxyl-free radicals. Depending on the
locations of methyl groups on their chromanol ring, tocopherols
and tocotrienols can be distinguished into four isomeric forms:
alpha (a), beta (b), gamma (g), and delta (d).
Apart from tocotrienol’s antioxidant, anti-inflammatory, anti-
angiogenic, antineurodegeneration, antihypercholesterolemic and
antimicrobial properties, emerging in vitro and in vivo evidences
have manifested the anticancer activity of tocotrienol on numerous
human cancer cells including prostate, breast, colon, liver and
gastric (Agarwal et al, 2004; Nesaretnam et al, 2004; Sylvester and
Shah, 2005; Eitsuka et al, 2006; Kumar et al, 2006; McAnally et al,
2007) (reviewed in (Sen et al, 2007)). For example, a recent study
(Srivastava and Gupta, 2006) has demonstrated that treatment of
PCa cell lines (LNCaP, DU145, PC-3) with tocotrienol-rich fraction
(TRF) resulted in significant decreases in cell viability and colony
formation capability. More interestingly, TRF was able to
selectively spare the normal human prostate epithelial cells, an
important characteristic of effective chemoprevention strategy.
However, it should be noted here that the TRF used in the study
was a mixture of various vitamin-E isomers. Thus, it was not
possible to determine which isomer possesses the highest potency
in eliminating proliferating prostate cancer cells selectively, let
alone the discovery of molecular pathways responsible for the
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sinhibitory effect. In other studies (McAnally et al, 2003; Conte
et al, 2004; Vraka et al, 2006) g-T3 isomer was reported to suppress
prostate cancer cell growth with IC50 values for PC-3 between 25
and 51mM, although how the cell responds to the other isomers was
not investigated.
Although scientific evidences evoking suppression of cancer
cells by T3 are increasing, the exact pathways involved in
T3-induced apoptosis remain elusive. Initially, T3 treatment was
shown to induce apoptosis through a p53-dependent mechanism
(Agarwal et al, 2004). Using p53
þ human colon carcinoma RKO
cells, researchers demonstrated that TRF-induced activation of the
Bax gene through upregulation of the p53 protein. This was
associated with the release of cytochrome c from nucleus to
cytosol, induction of Apaf1 oligomerisation as well as activation of
caspase 9. Meanwhile, the T3-induced p53 expression was also
found to result in downregulation of Bcl-2 level, which eventually
triggers apoptotic-signalling cascade by increasing the bax/bcl-2
ratio. In addition to p53 pathway, phosphatidylinositol-3-kinase-
dependent kinase (PI3K)/PI3K-dependent (PDK1) mitogenic-
signalling cascade (Samant and Sylvester, 2006) and NF-kB (Ahn
et al, 2007) pathways have both been suggested to contribute to
T3-induced apoptosis. For example, in g-T3-treated cancer cells,
inactivation of PDK1 and Akt as well as downregulation of their
downstream effectors such as FLICE-inhibitory protein (FLIP) and
phospho-NF-kB were observed. FLIP reduction was shown to
promote the cleavage of caspases 3 and 8, which results in growth
arrest and apoptosis in T3-treated cells. Taken together, it seems
that T3-induced apoptosis in cancer cells may involve activation/
inactivation of multiple-signalling pathways.
MATERIALS AND METHODS
Prostate cancer cell lines, cell culture conditions and
chemicals
The human androgen-dependent PCa cells (LNCaP), human andro-
gen-independent PCa cells (PC-3) (ATCC, Rockville, MD, USA) were
maintained in their respective medium recommended by ATCC
(Invitrogen, Carlsbad, CA, USA) supplemented with 2mmoll
 1
L-glutamine, 10% fetal calf serum (FCS) and 2% penicillin
streptomycin at 371Ci n5 %C O 2. The immortalised human prostate
epithelial cells (PZ-HPV-7) (ATCC, Rockville, MD, USA) were
maintained in keratinocyte serum-free medium (K-SFM) supplemen-
ted with bovine pituitary extract (BPE, 0.05mgml
 1)a n dh u m a n
recombinant epidermal growth factor (EGF, 5ngml
 1). Docetaxel
(Calbiochem, San Diego, CA, USA) and JNK inhibitor, SP600125
(Sigma-Aldrich, St Louis, MO, USA), were dissolved in dimethyl-
sulphoxide (DMSO). The treatment solutions were diluted in culture
medium to obtain the desired concentrations.
Tocotrienol and tocopherol isomers
Tocotrienol and tocopherol isomers were extracted and purified
from palm oil using Davos separation technology. The extraction
facility is located at Tuas Singapore. Crude palm oil feed was
purchased from Kuala Lumpur Kepong Berhad. Using the
corresponding tocotrienol isomers as the reference standard, the
purity of T3 and T isomers was verified to be X97% by high
performance liquid chromatography percentage area (% area).
Cell viability study and time course experiment
For cell viability study, 5 10
3 cells resuspended in 100ml medium
were plated into each well of a 96-well plate. The cells were then
treated with different concentrations (20, 40, 60, 80, 100mM) of the
vitamin-E isomers for 24- and 48-h. After the treatment, 20mlo f
MTT solution was added into each well and the cells were
incubated at 371C for 2h. The formazan crystals were then
resuspended in 200ml of DMSO and the intensity at 595nm were
measured. For JNK inhibitor study, cells were pre-treated with
20mM of SP600125 for 8h prior to the addition of vitamin-E
isomers. For time course study, 5 10
3 cells (LNCaP and PC3)
were treated with IC50 concentrations of the vitamin-E isomers and
were subjected to the MTT assay at the indicated time point. If IC50
for the isomer is 4100mM, 100mM will be used as treatment
dosage. Each experiment was repeated three times in triplicate
wells and the growth curves showed the means and s.d.
To test the effect of g-T3 on the cytotoxicity of Docetaxel, cells
were pre-incubated with g-T3 for 3h before addition of 20 and
100nM of Docetaxel. After 24h, cells were subjected to western
blotting and MTT assays respectively.
Flow cytometry
Cell cycle distribution was examined using flow cytometry. Briefly,
cells were harvested by trypsinisation, fixed in 70% ethanol at 41C
overnight, and then resuspended in PBS. After incubation at 41C
overnight, 2 10
6 cells were incubated with 20mgml
 1 propidium
iodide and 2mg RNase A for 15min at 371C. Cells were then
examined by BD SLRII cytometer and the results were analysed
using ModFit software (Becton Dickinson, Mountain View, CA,
USA). Data were expressed as the percentage of cell cycle
distribution in the entire population.
Matrigel-invasion assay
Matrigel-invasion assay was performed according to a method
published earlier with modifications (Albini et al, 1987). Briefly,
the invasive androgen-independent PCa cells (PC-3) were pre-
incubated in a serum-free RPMI-1640 medium with or without
g-T3 isomers for 24h. The PC-3 cells, (2.5 10
5) resuspended in
500ml of serum-free RPMI-1640 containing 0.1% bovine serum
albumin, were then added to the upper chamber of an 8-mm pore
size insert (Millipore, Bedford, MA, USA) manually coated with
Matrigel (0.5mgml
 1) (BD Bioscience, Bedford, MA, USA). Five
hundred microliters of invasion buffer containing fibronectin
(10mgml
 1) and RPMI-1640 supplemented with 10% FCS were
added in the lower chamber as a chemo-attractant. The PC-3 cells
were incubated at 371C for 24h in 5% CO2-humidified conditions.
At the end of incubation period, inserts were stained with Diff-
Quick staining solution (Fischer Scientific). Non-invaded PC-3
cells on the inside of the insert were scraped off with a cotton swab.
The PC-3 cell invasions were then examined by a phase-contrast
microscope. The invaded cells were extracted using extraction
buffer (Millipore, Bedford, MA, USA) and the cell number was
estimated based on absorbance at 595nm.
Western blotting
Detailed protocols have been described earlier (Chu et al, 2006).
Briefly, cell lysates were prepared by suspending cell pellets in lysis
buffer (50mmoll
 1 Tris-HCl (pH 8.0), 150mmoll
 1 NaCl, 1%
NP40, 0.5% deoxycholate, 0.1% SDS, 1mgml
 1 aprotinin, 1mgml
 1
leupeptin and 1mmoll
 1 phenylmethylsulphonyl fluoride). For
nuclear protein extraction, NucBustert protein extraction kit was
used. Protein concentration was measured using the DC Protein
Assay kit (Bio-Rad, Hercules, CA, USA). Equal amount of protein
(30mg) was loaded onto a 10% SDS polyacrylamide gel for
electrophoresis and then transferred onto a polyvinylidene
difluoride membrane (Amersham, Piscataway, NJ, USA). The
membrane was then incubated with primary antibodies for 1h at
room temperature against E-cadherin (BD Biosciences, Bedford,
MA, USA), a-catenin, b-catenin, g-catenin, Id-1, Id-3, EGF-R,
phosphor-c-jun, phospho-ATF2, cleaved PARP, vimentin,
a-smooth muscle actin, twist (Santa Cruz Biotechnology, CA,
USA), Phospho-ikB-a (Ser32/36), Phospho-IKK a (Ser180)/IKK b
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sTable 1 Effect of vitamin-E isomers on prostate cells
(A)
Mean cell viability in percentage (relative to control)
Tocopherols (T)
ab c d
Incubation (hours)
24 48 24 48 24 48 24 48
Dose (lM) 2 0 4 0 8 0 2 08 0 2 04 08 02 0 8 0 2 04 08 0 2 0 8 0 2 0 4 0 8 0 2 0 8 0
LNCaP 106±8 105±59 2 ±7 102±78 7 ±59 6 ±89 2 ±58 8 ±5 103±78 8 ±48 1 ±77 9 ±76 7 ±78 1 ±45 6 ±4 103±79 8 ±59 3 ±78 4 ±78 3 ±5
PC-3 96±7 101±69 3 ±59 4 ±69 1 ±49 8 ±99 8 ±79 5 ±89 6 ±99 7 ±69 2 ±89 3 ±58 4 ±78 8 ±67 8 ±69 4 ±49 2 ±68 7 ±59 8 ±88 5 ±7
PZ-HPV7 108±8 102±59 8 ±5 103±8 104±6 103±8 104±59 9 ±11 96±89 6 ±89 9 ±6 106±5 100±89 7 ±89 9 ±78 4 ±49 5 ±49 0 ±79 0 ±59 4 ±6
Tocotrienols (T3)
ab c d
Incubation (hours) 24 48 24 48 24 48 24 48
Dose (lM) 2 04 08 0 I C 50 20 80 20 40 80 IC50 20 80 20 40 80 IC50 20 80 20 40 80 IC50 20 80
LNCaP 98±69 7 ±49 0 ±7U D 9 6 ±79 4 ±89 3 ±89 6 ±79 1 ±7U D 9 7 ±78 9 ±79 3 ±58 9 ±76 7 ±49 28 9 ±84 7 ±49 6 ±67 9 ±64 7 ±47 5 8 9 ±64 2 ±2
PC-3 105±6 110±59 8 ±5U D 9 9 ±8 106±77 8 ±46 1 ±43 1 ±35 4 6 9 ±48 ±26 3 ±33 9 ±24 ±13 2 5 1 ±46 ±27 3 ±85 2 ±31 0 ±24 1 6 1 ±31 5 ±2
PZ-HPV7 98±59 7 ±4 105±6 UD 101±4 101±89 8 ±6 102±69 1 ±5U D 9 3 ±89 1 ±59 4 ±7 101±39 1 ±5U D 8 8 ±78 6 ±49 7 ±59 9 ±59 6 ±8U D 8 9 ±78 6 ±6
(B) Mean cell proliferation in percentage (relative to time 0th)
Control 100lM a-T3 IC50 b-T3
Incubation (hours) 0 24 48 72 120 144 0 24 48 72 120 144 0 24 48 72 120 144
LNCaP 100 101±5 121±8 137±6 123±11 157±9 100 95±58 7 ±6 107±5 113±8 122±10 100 79±86 4 ±84 4 ±65 9 ±74 8 ±9
PC-3 100 102±7 106±5 108±9 155±8 174±11 100 102±7 106±9 118±6 136±9 144±9 100 82±84 3 ±64 8 ±52 6 ±42 2 ±5
IC50 c-T3 IC50 d-T3
Incubation (hours) 0 24 48 72 120 144 0 24 48 72 120 144
LNCaP 100 59±84 9 ±54 5 ±53 7 ±63 2 ±6 100 57±45 3 ±43 4 ±21 5 ±51 7 ±3
PC-3 100 53±61 0 ±38 ±32 ±23 ±2 100 59±51 8 ±39 ±25 ±23 ±2
(A) Cell viability was examined by MTT assay after treatment with different vitamin-E isomers for 24- and 48-h. Note that vitamin-E isomers, particularly tocotrienols, selectively affect the viability of the prostate cancer cells at a
different degree, but do not have a significant effect on the non-tumorigenic prostate epithelial cells. PC-3 is more responsive to vitamin-E isomers compared with LNCaP. (B) LNCaP and PC-3 growth rate in the presence of g-T3 at
IC50. The IC50 dose levels correspond to that in Table 1A. For a-T3, 100mM was used. UD indicates undetermined IC50.
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s(Ser181), Phospho-SAPK/JNK (Thr183/Tyr185) G9, SAPK/JNK,
NF-kB p65 (5A5) (Cell Signaling Technology Inc., Beverly, MA,
USA), Snail (Abcam, Cambridge, UK). After incubation with
appropriate secondary antibodies, signals were visualised by ECL
western blotting system (Amersham, Piscataway, NJ, USA).
Expression of b-actin and histone H1 were assessed as an internal
loading control for total cell lysate and nuclear protein lysate,
respectively.
RESULTS
Antiproliferation effect of vitamin-E isomers
PCa cells were treated with vitamin-E isomers for 24- and 48-h at
increasing dosage (low: 20mM, medium: 40mM and high: 80mM)
and for varying time points. Our results showed that vitamin-E
isomers did not affect significantly the proliferation rate of normal
prostate epithelial cells (PZ-HPV-7), but significantly suppressed
the proliferation of LNCaP and PC-3 (Table 1A). The dose to
suppress 50% cell growth (IC50) in LNCaP and PC-3 was inversely
proportional to the length of incubation time. Surprisingly, PC-3
cells were more sensitive to the growth inhibition of the vitamin-E
isomers than LNCaP cells. The inhibition of cell proliferation was
significantly stronger for T3 isomers in PC-3, particularly for g-T3,
which showed a dose- and time-dependent inhibition (Table 1B).
Although d-T3 was more potent in suppressing cell growth in
LNCaP (Table 1A), the IC50 value was significantly higher than that
for g-T3 in PC-3. Separately, g-T was also found to induce
apoptosis in LNCaP cells (Jiang et al, 2004) at a dose similar to
g-T3. Based on the IC50 values in PC-3 cells incubated with various
isomers for 24-h, the order of inhibitory effect is g-T34d-T34
b-T34g-T4d-TEa-T3Ea-TEb-T. For the subsequent experi-
ments, we investigated the most potent isomer for PC-3 (g-T3) as
they are in general considered more invasive and resistant to
chemotherapeutic agents compared with LNCaP cells (Coppe et al,
2004; Ghosh et al, 2005).
To study the mechanism responsible for g-T3-induced growth
inhibition, cell cycle distribution of the cells with or without g-T3
treatment for 24h were analysed by flow cytometry. Consequently,
treatment of cells with g-T3 (IC50–95) resulted in an induction of
sub-G1 cell population, indicating the presence of apoptotic cells
after the treatment (Figure 1A). The proportion of apoptotic cells
(sub-G1 fraction) increased in a dose-dependent manner. It is
noteworthy that although g-T3 was previously reported to induce
G1 arrest in some cell lines (Mo and Elson, 1999), we did not
observe a significant increase of G1 population in prostate cancer
cells that were treated with g-T3. Consistent with the induction of
sub-G1 cell population in flow cytometry, activation of procaspase
3, 7, 8, 9 as well as PARP, as evidenced by the appearance of the
cleaved products, were observed in PC-3 cells treated with different
g-T3 dosage for 24h. Downregulation of bcl-2 was also detected
after the treatment, although bax expression was not affected,
which is likely because of the lack of p53 expression in PC-3 cells
Ctrl IC95 -T3 IC75 -T3 IC50 -T3
P
C
-
3
L
N
C
a
P
Antibody Control
PARP 116 kDa
Cleaved PARP 85 kDa
Procaspase 7 35 kDa
Cleaved caspase 7 20 kDa
Procaspase 8 57 kDa
Cleaved caspase 8 41/43 kDa
Cleaved caspase 9 37 kDa
Procaspase 3 32 kDa
Cleaved caspase 3 19/17 kDa
Bcl-2 26 kDa
Bax 20 kDa
  Actin 43 kDa
Dosage dependent/ M Time dependent / hours PC-3
Antibody Antibody 0  M 30  M  T3 30  M  T3
  89 kDa Id-1
  19/17 kDa
89 kDa
  20 kDa
  43 kDa
  17 kDa Cleaved caspase 9
Cleaved caspase 8
Cleaved caspase 7
Cleaved caspase 3
Cleaved PARP
  Actin
Id-1
Cleaved caspase 9
Cleaved caspase 8
Cleaved caspase 7
Cleaved caspase 3
Cleaved PARP
  Actin 43 kDa
  89 kDa
  19/17 kDa
89 kDa
  20 kDa
  43 kDa
  17 kDa
43 kDa
PZ-HPV-7 PZ-HPV-7
0  M 0  M 90  M  T3 90  M  T3 0  M
PC3 LNCaP
48 24 12 6 Control 40 20 10
sub G1
Ctrl 0.9    51.1    21.8    35.2 2.1     77.4     7.7     12.6
IC50 18.4    64.1      7.6      9.2 29.1     57.1     3.8       9.0
IC75 24.7    52.5    10.9    11.7 66.1     26.8     3.3       3.6
IC95 47.3    31.1      7.8    13.0 81.0     14.2     2.6       1.9
PC-3
Mean percentage of cell population/%
LNCaP
G1 G2 S sub G1 G1 G2 S
Figure 1 Induction of apoptosis by g-T3 treatment. (A) Cell cycle analysis by flow cytometry. Control cells and treated cells incubated with g-T3 at IC50
for 24-h were subjected to flow cytometry analysis. Note that the sub-G1 population appears after treatment. (B)I C 50 time-dependent and 24-h dose-
dependent activation (in hrs and mM respectively) of the pro-apoptosis pathway in PC-3. Note that g-T3 induces activation of the critical molecules (cleaved
caspase 3, 7, 8, 9, PARP) and modulate the ratio between the amounts of bcl-2 and bax in a cell dose- and time-dependent fashion. (C)I C 50 g-T3 activates
pro-apoptotic genes and suppresses pro-survival genes expression on LNCaP and PC-3 but not on non-tumorigenic prostate epithelial cells (PZ-HPV) for
24-h incubation period.
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s(Figure 1B). Meanwhile, these g-T3-mediated activation of the
proapoptotic proteins as well as the change of bcl-2/Bax ratio were
in a dose- and time-dependent manner (Figure 1B), consistent with
the effect of g-T3 treatment on inhibition of cell proliferation. In
addition, activation of these pro-apoptotic genes after IC50 g-T3
treatment (Figure 1C) were only observed in PC-3 and LNCaP cells,
but not in PZ-HPV-7, indicating that g-T3 specifically induced
apoptosis of androgen-independent prostate cancer cells.
c-T3 downregulates the pro-survival signalling pathways
Although NF-kB was reported to be constitutively activated in PC-
3 (Dhanalakshmi et al, 2002), the possibility that g-T3-induced cell
apoptosis attributable to the suppression of NF-kB activation was
considered. The NF-kB activities of PC-3 treated with g-T3 at either
different dosages or at IC50 for different periods were measured by
examining the translocation of NF-kB subunit p65. As illustrated
in Figure 2A, g-T3 treatment suppressed constitutive NF-kB p65
activity in a dose-dependent and time-dependent manner. The
effect of g-T3 on NF-kB signalling was further explored by
examining the expression of other upstream regulators, such as
phospho-ikBa/b and ikBa/b.I ng-T3-treated PC-3 cells, a time-
and dose-dependent decrease in the level of the phosphorylated
IkBa/b were observed (Figure 2A). This is associated with the
increase in the level of IkBa/b, as well as an inhibition of NF-kB
p65 nuclear translocation. These results indicate that g-T3
suppressed NF-kB activity through the dephosphorylation and
accumulation of IkBa/b.
Surprisingly, we found that g-T3 treatment also downregulate a
number of the key proteins that are involved in the development
and progression of prostate cancer. As shown in Figure 2B, EGF-R
expression was significantly suppressed to almost an undetectable
level by treatment with increasing dosages of g-T3. Similar effect
on Id-1 and Id-3 protein level was observed. As EGF-R and Id
protein family are essential for cancer cell growth and survival,
their downregulation may be associated with the g-T3-induced
growth arrest and apoptosis.
Activation of pro-apoptotic pathway by c-T3 treatment
The c-Jun N-terminal kinase is an evolutionarily conserved serine/
threonine protein kinase that is activated by stress and genotoxic
agents. JNK phosphorylates the amino terminal of all three Jun
transcription factors and ATF-2 members of the AP-1 family. The
activated transcription factors modulate gene expression to
generate appropriate biological responses, including cell migration
and cell death. When PC-3 cells were treated with various doses of
g-T3, a dosage- and time-dependent increase in JNK phosphoryla-
tion activities were detected (Figure 3B). Meanwhile, phosphoryla-
tion of the JNK downstream effectors such as ATF-2 or c-jun were
all upregulated by g-T3, supporting that JNK-signalling pathway
was activated by the g-T3.
To further confirm the importance of JNK activation in
g-T3-induced apoptosis in PCa cells, we investigated whether
inactivation of JNK with a specific inhibitor, SP600125, could
protect cells from g-T3. As shown in Figure 3A, co-treatment of
g-T3 together with 20mM of SP600125, a dose that was previously
determined to inhibit JNK activity in the same cell lines (Uzgare
and Isaacs, 2004), decreased the percentage of apoptotic cells
compared with that treated with g-T3 alone, confirming that JNK
activation may be required for g-T3-induced apoptosis.
Effect of c-T3 on inhibition of cell invasion
Although g-T3 has been shown to have antiproliferation effect on
many cancers, it is not clear if it affects cancer metastasis.
Therefore, we examined whether g-T3 could suppress the invasive
ability of the prostate cancer cells. As shown in Figure 4B, using
matrigel-invasion assay, we found that g-T3-treated (IC50) PC-3
Antibody Control 10 20 40
phospho-i B  40 kDa
i B 39 kDa
  Actin 43 kDa
Antibody Control 10 20 40 Control 6 12 24 48
Control 6 12 24 48
NF- B p65 65 kDa
Histone H1 32 kDa
Dosage dependent/ M Time dependent / hours
Dosage dependent/ M  Time dependent / hours
PC-3
Antibody Control 10 20 40 Control 6 12 24 48
EGF-R 170 kDa
Id-1 15 kDa
Id-3 15 kDa
  Actin 43 kDa
Dosage dependent/ M Time dependent / hours
PC-3
Figure 2 Inactivation of pro-survival pathways by g-T3. (A) Effect of g-T3 on the activity of NF-kB pathway was examined by IC50 time-dependent and
24-h dose-dependent western blotting (in hours and mM respectively). Note that nuclear translocation of NF-kB p65 and phosphorylated ikB were inhibited
by g-T3 treatment. (B) Treatment of g-T3 also resulted in downregulation of Id family proteins and EGF-R in PC-3 cells.
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scells for 24h showed an at least 2.5-time lower invasion capability
compared with the untreated control as evidenced by a decrease in
the number of cells invaded through the matrigel layer. This
inhibitory effect on cell invasion was not the result of cell growth
inhibition induced by g-T3 as the number of viable cells added into
the invasion chamber were the same. These results indicate that
g-T3 is able to inhibit the invasion ability of PCa cells, independent
to their cytotoxic effects.
Downregulation of E-cadherin expression is one of the most
frequently reported characteristics of metastatic cancers. Restora-
tion of E-cadherin expression in cancer cells leads to the
suppression of metastatic ability (Morton et al, 1993; Chu et al,
2006). In PCa, downregulation of E-cadherin expression is
correlated with high-grade tumours and poor prognosis (van Oort
et al, 2007), indicating their roles in PCa progression. Interestingly,
we found that E-cadherin and g-catenin protein expression were
upregulated whereas E-cadherin’s repressor (snail) (Cano et al,
2000) were downregulated after treatment with g-T3 (Figure 4A),
although the expression for b-catenin remained constant at all
treatment dosages and time points. Owing to the deletion of the
a-catenin in PC-3 cells (Morton et al, 1993), there was
no expression detected. Separately, the mesenchymal markers
(vimentin, a-SMA and twist) were all downregulated after
treatment with g-T3 for 24h.
Effect of c-T3 treatment on Docetaxel-induced apoptosis
Many of the natural products, such as aged garlic extract (Howard
et al, 2007) or lupeol (Prasad et al, 2008) which are extracted from
fruit or plant have been shown to have a chemosensitisation effect.
Although it is not clear if g-T3 may affect the sensitivity of cancer
cells to chemotherapy, previous study has shown that it did
enhance the effectiveness of radiation treatment against prostate
tumour (Kumar et al, 2006). To test if g-T3 can act synergistically
with a chemotherapeutic agent, we have compared the effect of
g-T3 alone or in combination with Docetaxel. As shown in
Figure 5A, the percentage of apoptotic cells in PC-3 and LNCaP cell
lines following co-treatment of Docetaxel with g-T3 for 24h was
significantly higher than that treated with g-T3 or Docetaxel alone.
Using western blotting, we further demonstrated that g-T3 co-
treatment with Docetaxel enhances cell apoptosis through activa-
tion of pro-apoptotic proteins (cleaved PARP, caspases 3, 7, 8, 9)
and downregulation of pro-survival proteins (Id-1, EGF-R, ikB and
NF-kB p65) (Figure 5B). The level of apoptotic cells is in stark
contrast to the g-T co-treatment with Docetaxel. These results
suggested that g-T3 and Docetaxel might have a synergistic effect
against prostate cancer cells.
DISCUSSION
Tocotrienol isomers have been earlier shown to inhibit cancer cell
proliferation, promote cell cycle arrest, and decrease angiogenesis
(reviewed in (Sen et al, 2007)). The present report shows that,
among eight vitamin-E isomers, g-T3 inhibits PCa cell proliferation
through modulation of pro-survival (Id-1, Id-3, EGF-R and NF-kB)
and pro-apoptotic (JNK) pathways. Meanwhile, we demonstrated
for the first time that g-T3 inhibits cell invasion by restoration of
the E-cadherin, g-catenin expression and suppression of mesen-
chymal markers. Together with the finding that g-T3 enhanced the
anticancer effect of Docetaxel, our study provides strong evidences
that g-T3 may be developed as a safe and effective anticancer agent
for the treatment of prostate cancer.
It is worth noting that published reports (McAnally et al, 2003;
Conte et al, 2004; Vraka et al, 2006) indicated earlier that g-T3
isomer suppressed prostate cancer cell growth. In these reports,
g-T3’s IC50 value for PC-3 cells varied between 25–51mM.T h e
difference between our result and those reported previously could
PC-3
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Figure 3 Jun N-terminal kinase (JNK) activation is involved in g-T3-induced apoptosis. (A) Cell viability, after incubation with g-T3 and JNK inhibitor
(SP600125) for 24-h, was examined by an MTT assay. Note that the addition of JNK inhibitor alleviates the cytotoxicity of g-T3 in PC-3, suggesting that JNK
mediates the antiproliferation effect of g-T3. (B) JNK activity after 24-h dose-dependent and IC50 time-dependent g-T3 treatment (in mM and hours
respectively) and was found to be elevated by measuring the phosphorylation levels of MKK4, SAPK/JNK, c-jun and ATF-2. Thus, confirming the involvement
of JNK in g-T3 anticancer property.
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sbe due to several reasons. Firstly, the IC50 values reported earlier
were for cells supplemented with g-T3 for 72-h incubation period.
Secondly, the g-T3 isomer used in those studies may have different
purity than that used in this study (X97%). Thirdly, the difference
in the proliferation assay used may result in data variation.
Although g-T3 treatment caused significant apoptosis in prostate
cancer cells, breast cancer cells (Guthrie et al, 1997), gastric cancer
cells (Sun et al, 2008) and human myeloid cells (Ahn et al, 2007),
several published reports have also indicated that d-T3 is equally
potent for inducing apoptosis in other cancer types (He et al, 1997;
Qureshi et al, 2000; Wada et al, 2005). For example, HepG2 and B16
melanoma cells treated with d-T3 showed a significant reduction in
cell viability with IC50 9.6 and 10mM, respectively. In our
experiments with the androgen-dependent LNCaP cell line, d-T3 is
more potent in suppressing the cell proliferation of this cell type
among the eight vitamin-E isomers investigated (Table 1A). Taken
together, it seems likely that g-a n dd-T3 may possess tumour-
suppressing activities with different cell type specificity and potency.
In this study, we demonstrated that g-T3 suppressed constitutive
NF-kB activity through inhibition of ikB kinase activation, leading
to apoptosis in PCa cells. This is in agreement with the previous
study which showed that g-T3 can interfere with the TNF-induced
NF-kB activation pathway in human myeloid KMB-5 cells and
several other cancer cell lines (Ahn et al, 2007). In addition to their
findings, we have demonstrated that g-T3-induced NF-kB inactiva-
tion also downregulates the level of bcl-2 in a dosage-dependent
and time-dependent fashion. Consequently, this induced apoptosis
through activation of caspases 3, 7, 8, 9 and PARP. Consistent with
previous results obtained with diverse cell lines differing in p53
status (Mo and Elson, 1999), our results showed that p53 is not
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Figure 4 Inhibition of cell invasion by g-T3 treatment. (A) 24-h dose-dependent and IC50 time-dependent g-T3 treatment induces the expression of
epithelial markers (E-cadherin, g-catenin), but suppresses the expression of mesenchymal markers (vimentin, twist and a-SMA) and E-cadherin’s repressor
(snail). (B) The invasive androgen-independent PCa cells (PC-3) treated with the indicated dosage of g-T3 was harvested and then plated into the Matrigel-
coated (0.5mgml
 1) insert. Cells invaded through the membrane were stained with crystal violet and the images were photographed under a microscope.
After being lysed with extraction buffer, intensity at 595nm was measured.
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srequired for g-T3-induced apoptosis, as the p53-null cell lines
(PC-3 and HL-60 (Mo and Elson, 1999)) are still responsive to g-T3
treatment. It is worth noting that g-T3 was previously demon-
strated to abolish NF-kB activation induced by epidermal growth
factor (EGF) and other pro-inflammatory cytokines (Ahn et al,
2007). Although the molecular mechanism involved was not clear
at that time, the authors proposed that g-T3 may act through a
common step in the suppression of NF-kB. Our result revealed that
downregulation of EGF receptor (EGF-R) was correlated to
g-T3-induced NF-kB inactivation (Figure 2B). This finding may
explain why g-T3 was able to suppress NF-kB activation by EGF
treatment in KBM-5 cells (Ahn et al, 2007). Interestingly, the
androgen-independent prostate cancer cell line PC-3 was found to
be more sensitive to g-T3 treatment than the androgen-dependent
LNCaP cells. PC-3 cells were found to have constitutive NF-kB
activation and are in general more resistant to chemotherapeutic
drug-induced apoptosis than the LNCaP cells. Although the exact
reason for this observation is unclear, but based on the fact that
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Figure 5 Synergistic effect of g-T3 on Docetaxel-induced apoptosis. (A) Effect of Docetaxel and g-T3 co-treatment for 24-h. Cells were incubated with
different dosages of g-T3 and 100nM of Docetaxel for 24h. Cell viability was examined by MTT assay. The percentage of apoptotic PC-3 and LNCaP cells
following co-treatment of Docetaxel and g-T3 was significantly higher than that treated with either agent alone. (B) Using western blotting, we further
demonstrated that g-T3 co-treatment with Docetaxel for 24-h enhances PC-3 cell apoptosis through activation of pro-apoptotic molecules (cleaved PARP,
caspases 3, 7, 8, 9). Additional suppression of proliferation genes were also confirmed for Id-1, EGF-R, ikB, and NF-kB p65. (C) Proposed T3 anticancer
pathway in PCa cells.
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snon-tumorigenic prostate epithelial cells are highly resistant to g-
T3 as well, it is possible that g-T3 may preferentially target the cells
with higher malignant phenotype.
We believed that one possible mechanism by which g-T3 could
mediate its effects on the NF-kB pathway is through the
suppression of Id-1 and EGF-R (Ling et al, 2003). We have
previously demonstrated that ectopic Id-1 expression in LNCaP
cells resulted in increase of NF-kB transactivation activity and
nuclear translocation of the p65 and p50 proteins, which was
accompanied by upregulation of their downstream effectors Bcl-xL
and ICAM-1. In addition, inactivation of Id-1 by its antisense
oligo-nucleotide and retroviral construct in DU145 cells resulted in
the decrease of nuclear level of p65 and p50 proteins, which was
associated with increased sensitivity to TNF-induced apoptosis.
Considering these findings, our results strongly suggest that Id
gene family may be one of the upstream regulators of NF-kB that is
targeted directly by g-T3, and inhibition of NF-kB-signalling
pathway may be responsible for g-T3-induced antiproliferation.
In this study, we also showed that c-Jun N-terminal kinase
participates in g-T3-induced apoptosis. When PCa cells were
treated with g-T3, a series of molecules associated with JNK
pathway, such as c-Jun and ATF-2 (Figure 3A), were activated
simultaneously. Meanwhile, we demonstrated that treatment of
JNK inhibitor (SP600125) protects the PCa cells from g-T3-induced
apoptosis (Figure 3A). This further confirms the involvement of
the JNK pathway in g-T3-induced apoptosis in PCa cells. It is
worth noting that the JNK pathway is also known to be involved in
cell apoptosis induced by the chemotherapeutic drug, Docetaxel
(Zhang et al, 2006). Taking these findings into consideration, we
therefore question whether g-T3 possesses synergistic interaction
with Docetaxel as a result of activation of the JNK pathway. To this
end, we compared the antiproliferation capability of Docetaxel
treatment alone, and co-treatment with g-T3. Remarkably, we
found that combined treatment of Docetaxel and g-T3, but not g-T,
resulted in higher proportion of apoptotic cells (Figure 5A). This
finding suggests a possible synergistic role of g-T3 with the
chemotherapeutic agent.
In this study, we determined that restoration of E-cadherin and
g-catenin expression, together with suppression of snail, a-SMA,
vimentin and twist, may account for g-T3’s inhibitory effect on
PCa cell invasion capability. Although the antiproliferation effect
of g-T3 has been reported in several cancer types (reviewed in (Sen
et al, 2007)), our results provide first evidence to suggest that it
may also be a potential agent for suppression of cancer invasion.
Downregulation of E-cadherin and upregulation of mesenchymal
markers (a-SMA, vimentin and twist) are some of the most
frequently reported phenomena in metastatic cancers (Morton
et al, 1993). It is suggested that loss of E-cadherin expression is
able to promote epithelial–mesenchymal transition (EMT), which
plays a key role in the progression of cancer cells to metastatic
stage. Although the precise mechanism responsible for E-cadherin
inactivation in cancer cells is not clear, alterations at transcrip-
tional level due to its repressor Snail seem to be one of the
mechanisms responsible for its decreased expression in several
cancer types. In this study, we found that the g-T3-treated PCa cells
showed increased E-cadherin expression (Figure 4A), which was
associated with reduced Snail protein expression and invasion
ability (Figure 4B). Catenins (a,g), a family of cytoplasmic
cadherin-binding proteins, link E-cadherin to the actin cytoske-
leton and are thought to be essential for normal E-cadherin
function. In our study, we found that g-T3 only upregulated the
expression of E-cadherin and g-catenin, but not a-catenin. The
expression for b-catenin remains static, similar to our previous
experiments using garlic derivatives (Chu et al, 2006). Although
PC-3 cells do not express a-catenin, a key molecule for functional
E-cadherin expression, g-T3 might restore the function of
E-cadherin through other molecules such as vinculin, which has
been reported to play a role in the establishment of the E-cadherin-
based cell adhesion complex (Hazan et al, 1997). Taken together,
our results suggest that g-T3 may suppress cancer metastasis
through induction of mesenchymal–epithelial transition (MET).
As summarised in Figure 5C, our results demonstrated that g-T3
is a potent and specific inhibitor of PCa cell proliferation
and invasion which acts through multiple molecular pathways.
As no side effect can be observed after long term intake of
natural T3 extract (Patel et al, 2006; McAnally et al, 2007)
(LD50X2000mgkg
 1, data not shown), g-T3 may be used alone
or in combination with chemotherapy for treating advanced
stage PCa.
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